QSARMDHGFR

Muhammad Waleed Iqbal1, Muhammad Ali Raza1, Xinxiao Sun1

  • 1State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, People's Republic of China.

Molecular diversity
|October 30, 2025
PubMed
概括

研究人员通过计算选FDA批准的药物以抑制肝细胞生长因子受体 (HGFR) 来确定潜在的新卵巢癌治疗方法. 像venetoclax这样的有希望的候选药物显示出高强度和低毒性,提供了更安全的治疗替代品.